Advertisement
HIMS vs HROW
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HIMS is a StrongBuy and HROW is a Buy.
HIMS in +5.63% Uptrend, advancing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HIMS advanced for three days, in 240 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
HIMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In 66 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 36 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
HIMS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HIMS crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for HIMS entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.719) is normal, around the industry mean (6.379). P/E Ratio (-41.935) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (2.624) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.686) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
HROW in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
HROW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 36 cases where HROW's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HROW's RSI Oscillator exited the oversold zone, 32 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for HROW just turned positive on October 20, 2026. Looking at past instances where HROW's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
Following a +5.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where HROW advanced for three days, in 236 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HROW as a result. In 67 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HROW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for HROW entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HROW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. HROW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HROW's P/B Ratio (66.319) is slightly higher than the industry average of (6.379). P/E Ratio (-27.162) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (183.387).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
HIMS | HROW | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 15 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 85 Overvalued | |
PROFIT vs RISK RATING 1..100 | 79 | 67 | |
SMR RATING 1..100 | 97 | 99 | |
PRICE GROWTH RATING 1..100 | 73 | 76 | |
P/E GROWTH RATING 1..100 | 98 | 12 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HIMS's Valuation (62) in the null industry is in the same range as HROW (85) in the Pharmaceuticals Other industry. This means that HIMS’s stock grew similarly to HROW’s over the last 12 months.
HROW's Profit vs Risk Rating (67) in the Pharmaceuticals Other industry is in the same range as HIMS (79) in the null industry. This means that HROW’s stock grew similarly to HIMS’s over the last 12 months.
HIMS's SMR Rating (97) in the null industry is in the same range as HROW (99) in the Pharmaceuticals Other industry. This means that HIMS’s stock grew similarly to HROW’s over the last 12 months.
HIMS's Price Growth Rating (73) in the null industry is in the same range as HROW (76) in the Pharmaceuticals Other industry. This means that HIMS’s stock grew similarly to HROW’s over the last 12 months.
HROW's P/E Growth Rating (12) in the Pharmaceuticals Other industry is significantly better than the same rating for HIMS (98) in the null industry. This means that HROW’s stock grew significantly faster than HIMS’s over the last 12 months.
| HIMS | HROW | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 80% |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 77% |
| Momentum ODDS (%) | 1 day ago 80% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 78% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 83% |
| Advances ODDS (%) | 7 days ago 86% | 1 day ago 82% |
| Declines ODDS (%) | 9 days ago 82% | 9 days ago 80% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 79% | 1 day ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HIMS’s FA Score shows that 0 FA rating(s) are green while HROW’s FA Score has 1 green FA rating(s).
- HIMS’s FA Score: 0 green, 5 red.
- HROW’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HIMS’s TA Score shows that 3 TA indicator(s) are bullish while HROW’s TA Score has 5 bullish TA indicator(s).
- HIMS’s TA Score: 3 bullish, 6 bearish.
- HROW’s TA Score: 5 bullish, 3 bearish.
Price Growth
HIMS (@Pharmaceuticals: Generic) experienced а -9.11% price change this week, while HROW (@Pharmaceuticals: Generic) price change was -2.59% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.25%. For the same industry, the average monthly price growth was -8.53%, and the average quarterly price growth was +7.66%.
Reported Earning Dates
HIMS is expected to report earnings on Mar 01, 2027.
HROW is expected to report earnings on Mar 08, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (+2.25% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
HIMS and
Correlation & Price change
A.I.dvisor tells us that HIMS and COTY have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HIMS and COTY's prices will move in lockstep.
| Ticker / NAME | Correlation To HIMS | 1D Price Change % | ||
|---|---|---|---|---|
| HIMS | 100% | -11.77% | ||
| COTY - HIMS | 31% Poorly correlated | +4.20% | ||
| HROW - HIMS | 29% Poorly correlated | +2.16% | ||
| AYTU - HIMS | 28% Poorly correlated | -2.19% | ||
| DERM - HIMS | 25% Poorly correlated | +1.12% | ||
| IRWD - HIMS | 25% Poorly correlated | +6.61% | ||
More | ||||
HROW and
Correlation & Price change
A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AQST. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AQST could also see price increases.
| Ticker / NAME | Correlation To HROW | 1D Price Change % | ||
|---|---|---|---|---|
| HROW | 100% | +2.16% | ||
| AQST - HROW | 34% Loosely correlated | -1.94% | ||
| AMRX - HROW | 33% Poorly correlated | +5.66% | ||
| AYTU - HROW | 28% Poorly correlated | -2.19% | ||
| RMTI - HROW | 27% Poorly correlated | -2.72% | ||
| TEVA - HROW | 27% Poorly correlated | +0.84% | ||
More | ||||